One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
This prospective, open-label, non-comparative, multicentre, long-term phase IV study is examining the efficacy and safety of somatropin [recombinant human growth hormone (rhGH)] in short children born small for gestational age (SGA) and its impact on the incidence of diabetes. This report is the first interim analysis of patients who have completed 1 year of treatment.
A total of 278 pre-pubertal patients were enrolled. Key eligibility criteria included height standard deviation score (HSDS) <−2.5; parental adjusted SDS <−1; birth weight and/or length <−2 SD and failure to show catch-up growth by ≥4 years of age. Patients were treated with rhGH 0.035 mg/kg/day. The primary objective was to evaluate the long-term effect of rhGH on carbohydrate metabolism [including fasting glucose, stimulated glucose (2-h oral glucose tolerance test, OGTT) and glycated haemoglobin (HbA1c)]. Secondary objectives included evaluation of height parameters [body height, HSDS, height velocity (HV), HVSDS]; insulin-like growth factor 1 (IGF-I) and insulin-like growth factor-binding protein 3 (IGFBP-3) serum levels during treatment; and incidence and severity of adverse events (AEs).
None of the children developed diabetes mellitus within the first year of treatment. Mean levels of fasting glucose, HbA1c and 2-h OGTT values remained stable during the study period. Treatment with rhGH was effective, as documented by all height parameters. Mean HSDS improved from −3.39 at baseline to −2.57 at Year 1. Mean HV increased markedly from 4.25 cm/year at baseline to 8.99 cm/year during the first year. Similarly, mean peak-centred HVSDS increased from −2.13 at baseline to +4.16 at Year 1. Mean IGF-I SDS and IGFBP-3 SDS also increased within the first year (by +1.80 and +0.41, respectively). 13 patients (4.7%) did not respond adequately to treatment (HVSDS <1); they were withdrawn from the study. In total, 192 children (69.3%) experienced treatment-emergent AEs; most (98.7%) were mild-to-moderate, and the majority (96.5%) were unrelated to study treatment.
This interim analysis shows that short children born SGA can be effectively and safely treated with rhGH and that rhGH treatment has no major impact on carbohydrate metabolism after the first year of treatment.
- Saenger P, Czernichow P, Hughes I, Reiter EO. Small for gestational age: short stature and beyond. Endocr Rev. 2007;28:219–51. CrossRef
- Lee PA, Chernausek SD, Hokken-Koelega AC, et al. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age. Pediatrics. 2003;111:1253–61. CrossRef
- Albertsson-Wikland K, Karlberg J. Postnatal growth of children born small for gestational age. Acta Paediatr Suppl. 1997;423:193–5. CrossRef
- Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab. 2007;92:804–10. CrossRef
- Bhargava SK, Sachdev HS, Fall CH, et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med. 2004;350:865–75. CrossRef
- Eriksson JG, Osmond C, Kajantie E, Forsén TJ, Barker DJ. Patterns of growth among children who later develop type 2 diabetes or its risk factors. Diabetologia. 2006;49:2853–8. CrossRef
- Sas T, De Waal W, Muler P, et al. Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab. 1999;84:3064–70.
- Sas TC, Gerver WJ, De Bruin R, et al. Body proportion during 6 years of GH treatment in children with short stature born small for gestational age participating in a randomised, double-blind, dose-response trial. Clin Endocrinol (Oxf). 2000;53:675–81. CrossRef
- Czernichow P. Growth hormone treatment strategy for short children born small for gestational age. Horm Res. 2004;62:137–40. CrossRef
- Cutfield WS, Lindberg A, Rapaport R, Wajnrajch MP, Saenger P. Safety of growth hormone treatment in children born small for gestational age: the US trial and KIGS analysis. Horm Res. 2006;65(Suppl 3):153–9. CrossRef
- Delemarre EM, Rotteveel J, Delemarre-van der Waal HA. Metabolic implications of GH treatment in small for gestational age. Eur J Endocrinol. 2007;157:S47–50. CrossRef
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9. CrossRef
- Katz A, Nambi SS, Malther K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrin Metab. 2000;85:2402–10. CrossRef
- World Health Organisation (WHO). Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation; 2006. http://whqlibdoc.who.int/publications/2006/9241594934_eng.pdf (Accessed January 13, 2014).
- Medical Dictionary for Regulatory Activities (MedDRA) preferred terms, version 14.0 or higher. http://www.meddra.org/how-to-use/support-documentation (Accessed January 13, 2014).
- Jung H, Rosilio M, Blum WF, Drop SL. Growth hormone treatment for short stature in children born small for gestational age. Adv Ther. 2008;25:951–78. CrossRef
- Cutfield WS, Jackson WE, Jefferies C, et al. Reduced insulin sensitivity during growth hormone therapy for short children born small for gestational age. J Pediatr. 2003;142:113–6. CrossRef
- Lebl J, Lebenthal Y, Kolouskova S, et al. Metabolic impact of growth hormone treatment in short children born small for gestational age. Horm Res Paediatr. 2011;76:254–61. CrossRef
- Romer T, Saenger P, Peter F, et al. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of growth hormone deficient children: results of a phase III study. Horm Res. 2009;72:359–69. CrossRef
- López-Siguero J, Borrás Pérez MV, Balser S, Khan-Boluki J. Long-term safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of Spanish growth hormone deficient children: results of a phase III study. Adv Ther. 2011;28:879–93. CrossRef
- Omokanye A, Onyekpe I, Patel L, et al. Defining criteria for poor responders to growth hormone (GH) in short children born small for gestational age (SGA). 37th meeting of the British Society for Paediatric Endocrinology and Diabetes, Reading; 2009 (Endocrine Abstracts 23 P10).
- One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Biologics in Therapy
Volume 4, Issue 1-2 , pp 1-13
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare
- Additional Links
- Recombinant human growth hormone
- Small for gestational age
- Industry Sectors
- Author Affiliations
- 1. Department of Endocrinology, von Haunersches Kinderspital, University Hospital Munich, Munich, Germany
- 2. Medical University, Gdansk, Poland
- 3. Department of Endocrinology, Children’s Health Research Institute, Warsaw, Poland
- 4. Department of Paediatric Endocrinology and Diabetology, Pomeranian Medical University, Szczecin, Poland
- 5. Department of Endocrinology, University of Medicine and Pharmacy “Gr.T.Popa”, Iasi, Romania
- 6. Department of Endocrinology, Tblisi State Medical University, Tblisi, Georgia
- 7. Sandoz Biopharmaceuticals, HEXAL AG, Industriestr. 25, 83607, Holzkirchen, Germany